Day 1Monday, 3 November 2025

CELLeBRAIN is a clinical-stage biotechnology company pioneering mesenchymal stem cell (MSC)-based gene therapy. Our proprietary platform overcomes key limitations of conventional gene therapy—such as poor tissue targeting and systemic toxicity—by leveraging the innate tumor- and injury-homing properties of MSCs to enable localized, effective delivery of therapeutic gene products. We have established a robust and scalable manufacturing system for producing off-the-shelf allogeneic therapeutic cells. CELLeBRAIN is actively pursuing strategic collaborations and investment opportunities to advance our global clinical trials and support commercialization efforts.

EG 427 is the global leader in non-replicating HSV-1 (nrHSV-1) vector technology in neurology. EG 427 has started a phase 1b/2a study in the US with its lead candidate, EG110A, in patients with neurogenic detrusor overactivity-related incontinence. EG110A is being developed to addresses multiple severe bladder diseases, including overactive bladder (OAB), and has the potential to be a major improvement over existing therapies, resulting in better care for patients and lower costs for healthcare systems. The company’s unique HERMES platform delivers pinpoint neurotherapeutics to treat prevalent diseases of the peripheral and central nervous system. Its vectors can achieve focal transduction in specific regions and then selective expression of transgenes in targeted subsets of neurons thanks to the control of sophisticated regulatory elements. With demonstrated clinical safety and possible repeated dosing, the large payload capacity of nrHSV-1 vectors allows for versatile DNA delivery for smarter genetic medicine

Founded by academic entrepreneurs, Pandorum Technologies is a tissue regeneration company. At Pandorum, we have developed a proprietary full-stack cGMP-compliant technology platform to manufacture human Mesenchymal stem cell (MSC) exosomes at scale, with tunable cargo molecules and tailored properties- such as anti-inflammatory, anti-fibrotic, neurogenesis, pro/ anti- angiogenesis- to promote functional regeneration of human tissues, such as, cornea, skin, cartlidgeand so on, with an eye towards multi-organ regeneration and longevity. Our flagship assets, powered by exosomes, are optimized for the human cornea and skin regeneration. The USFDA has granted Orphan designation to KuragenX for advanced Neurotrophic Keratitis- presently an untreatable type of corneal blindness. cGMP manufacturing is on-going, with the first-in-human studies planned for 2026, after due regulatory approvals.

Pandorum is supported by the Government of India and marquee investors, and has received notable awards. The company has R&D labs in Bangalore India and California USA, and works with partners globally. For more information: www.pandorum.com.

YolTech Therapeutics is a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines. Our approach combines innovative gene editing technologies with an advanced lipid nanoparticle (LNP) delivery system, creating a versatile platform designed to address a wide range of serious diseases. Central to our mission is the development of internal capabilities, including end-to-end manufacturing, to ensure the highest standards of quality and scalability. Our lead candidate, targeting ATTR, marks a significant milestone as China's first LNP-mediated in vivo gene editing therapy to enter clinical development. With promising early clinical outcomes, YolTech is also advancing therapies for familial hypercholesterolemia (FH) and primary hyperoxaluria type 1 (PH1). As a company dedicated to transforming the treatment landscape, YolTech continues to push the boundaries of what is possible in gene editing.

Lexogen is a leading company in RNA sequencing, providing innovative solutions for transcriptome analysis and RNA research. Our products and services are designed to meet the evolving needs of the scientific community, delivering end-to-end solutions for high-quality, reliable results.

Founded in 2020 and headquartered in Graz, Austria, myBIOS GmbH is an innovative biotechnology company built on more than 40 years of scientific expertise. The company specializes in the production of high-value recombinant proteins, including alternative proteins, industrial enzymes, and bioactive peptides, serving a broad range of industrial sectors such as pharmaceuticals, food and feed, cosmetics or materials. At myBIOS, our mission is to redefine the future of recombinant protein production through our proprietary methanol-free fermentation technology, utilizing the yeast Pichia pastoris (Komagataella phaffii). This platform, based on non-toxic inducers, establishes new industry standards for safety, sustainability, and cost-efficiency. By achieving high protein titres without the use of methanol, we significantly reduce environmental impact and regulatory complexity, enabling compatibility with non-ATEX-certified facilities and simplifying implementation. This positions our technology as a scalable and accessible solution with the potential to transform protein manufacturing across diverse industries. In addition to our technological innovations, myBIOS offers tailored services including individual strain development and optimization, process development, bioreactor scale-up experiments, and the evaluation and transition of methanol-based production processes to methanol-free systems. Through our commitment to delivering affordable, high-quality, and sustainable protein solutions, myBIOS is driving meaningful progress in biotechnology and industrial biomanufacturing.

Avenue Biosciences is a transatlantic biotechnology company dedicated to accelerating the discovery and development of protein biologics, so that no life-saving therapy goes unrealized because of production barriers. Avenue Biosciences has developed a proprietary protein engineering platform that allows the simultaneous analysis of thousands of natural and synthetic signal peptides to boost therapeutic protein production. Our technology is based on years of research from the University of Helsinki, and has wide applications across mRNA therapies, gene therapy vectors, antibody engineering, biosimilars, de novo proteins and more.

Based in Munich, leon-nanodrugs GmbH is a Pharmatech company specializing in the development of equipment for the encapsulation of genetic material and other pharmaceutical active substances into nanocarriers, such as lipid nanoparticles (LNPs). The company leverages its proprietary FR-JET® technology to build innovative solutions. Its equipment portfolio includes NANOscreen® for formulation screening (currently in development), NANOlab® for process development as well as NANOme® and NANOus® for GMP manufacture. These systems enable faster route to clinical batches and are suitable for both individualized scales and commercial production. LEON's platform aims to empower pharmaceutical companies, small biotech, research institutes, and CDMOs, to capitalize on advancements in advanced therapies.

Molecule is a decentralized biotech protocol, building a web3 marketplace for research-related IP. Our platform and scalable framework for biotech DAOs connects academics and biotech companies with quick and easy funding, while enabling patient, researcher, and funder communities to directly govern and own research-related IP.

AlphaMol Science Ltd is a clinical stage drug discovery company, focusing on G protein-coupled receptors (GPCRs) drug development. AlphaMol established a dedicated GPCR-purposed AI platform for drug discovery. In the GPCR-DOCK 2021 global contest, AlphaMol defeated Goolge's AlphaFold2 for the five nominated targets, with 60% higher accuracy. In 2022, AlphaMol obtained the best outstanding award in NVIDIA Inception contest for startups. In the same year, the cofounders of AlphaMol were in the list of "top 2%" scientists in the world. Thanks to the outstanding GPCR-AI drug discovery platform, AlphaMol managed to develop first-in-class clinical candidates within a few months. Our leading first-in-class MRGPRX2 antagonist has been recently approval by FDA in 02.2025. We started our clinical trail in 07.2025. Moreover, we made significant progresses for our GLP1R/GIPR/GCGR triple functional oral small peptide which only contains 8 amino acids. This oral peptide is even much better than Lilly's Tirzepatide in the head-to-head experiment, in the consideration of: gastrointestinal reactions, body weight loss, liver function improvement, and more importantly no lean loss. We plan to do the IND-enabling by the 2025Q4.

Glutagen, a biopharmaceutical company based in Melbourne, Australia, specialises in developing and commercializing innovative treatments for celiac disease and gluten-related disorders. Its leading product, GluteGuard, is the only clinically proven solution worldwide to help prevent the symptoms from accidental gluten exposure in celiac disease and related conditions. Awarded the 2023 Outstanding & Innovative New Consumer Healthcare Product by Consumer Healthcare Products Australia for its "life-changing impact," GluteGuard ranks among Australia’s fastest-growing over-the-counter digestive health brands. Following its success in Australia, GluteGuard is now available in over 4,000 Canadian pharmacies, including Walmart and Shoppers Drug Mart, and has been nominated for the 2026 Best New Product Awards in Canada.

Innovacell was originally founded in 2000 as a spin-off from the Medical University of Innsbruck in Austria, with the goal of commercializing innovative cell therapies. In 2021, the company underwent a corporate restructuring that included relocating its global headquarters to Tokyo, Japan. As a result, Innovacell now operates as a bi-national corporate group, comprising a parent company (Innovacell Inc.) based in Japan, and a wholly-owned subsidiary (Innovacell GmbH) in Austria.
Innovacell's pipeline is currently focused on cell-based therapies for incontinence, a condition that continues to be underdiagnosed and underserved despite its widespread impact. The company is currently developing three candidates: two in late-stage clinical development (ICEF15 and ICES13) and one preclinical candidate (ICEF16).
The company's lead candidate, ICEF15, is an autologous skeletal myoblast cell therapy designed to address the root causes of urge fecal incontinence, a debilitating condition with limited effective treatment options. ICEF15 is currently being evaluated in a pivotal, multi-regional Phase III clinical trial which spans 11 European countries as well as Japan.
Innovacell has received strong financial backing to support its clinical and commercial ambitions. In July 2022, the company completed a Series C financing round, raising 2.7 billion JPY (approximately USD 19 million at the time) in equity from a diverse group of investors. Additionally, Innovacell secured EUR 15 million (approx. USD 15 million) in venture debt from the European Investment Bank (EIB), a key endorsement of the company's innovation and potential impact.
Most recently, in July 2025, the company concluded a Series D financing round, raising over 7.0 billion JPY (around USD 48 million). Notable participants in this round included Alfresa Corporation, M&G Investments, Rheos Capital Works, UntroD, Happines Capital, SBI Investment, ASKA Innovation Fund, HKO Japan Venture Fund, and Arcus Investment.

Espervita Therapeutics is a preclinical stage company developing metabolic reprogramming therapies in areas of unmet medical need, with pipeline assets targeting liver (HCC, MASH, fibrosis) and kidney (CKD, PKD) diseases. The company's lead asset, EVT0185 is a first-in-class inhibitor of all three acetyl-CoA metabolic enzymes (ACLY, ACSS2, ACC). EVT1085's novel mechanism has demonstrated profound efficacy in multiple preclinical models of HCC, MASH and kidney disease, with the effects in HCC published in 2025 in Nature. On the heels of this successful preclinical program, EVT0185 has moved into IND-enabling studies and the company is seeking strategic partnership and fundraising opportunities to complete the IND-enabling program and advance the lead compound through first-in-human trials.

Chugai Pharmaceutical Co., Ltd. is a leading Japanese pharmaceutical company engaged in the research, development, manufacturing, sale, importation, and exportation of pharmaceutical products. Founded in 1925 and formally established in 1943, Chugai is headquartered in Tokyo and operates globally as a member of the Roche Group. Renowned for its innovation in drug discovery, Chugai specializes in oncology, immunology, and rare diseases, with a strong emphasis on antibody engineering and biotechnology. The company employs approximately 7,700 people and is publicly listed on the Tokyo Stock Exchange. Chugai’s strategic growth is guided by its “TOP I 2030” vision, aiming to become a top innovator in the healthcare sector.

Crossject is a specialty pharmaceutical company developing medicines for emergency situations utilizing its award-winning needle-free auto-injector ZENEO® platform and portfolio of drug /device combinations.

CROSSJECT is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) (contract number 75A50122C0003). The Company’s versatile ZENEO® platform is designed to enable patients or untrained caregivers to easily and instantly deliver a broad range of emergency drugs via intramuscular injection on bare skin or even through clothing.

Crossject's needle free auto-injection platform can be adapted to different liquid drug formulations in order to improve patients or caregiver usability, safety and injection reliability.

Crossject is currently ISO in-licensing opportunities synergistic to the ZENEO® auto injector in its IM and SC configurations.

Eydis Bio is a privately held biotechnology company based in Durham, North Carolina, dedicated to developing innovative therapies for autoimmune and inflammatory diseases. The company’s primary focus is on advancing a first-in-class, orally bioavailable TAK1 inhibitor that targets a critical regulatory node at the convergence of multiple pro-inflammatory signaling pathways. Unlike traditional therapies that block individual cytokines downstream, Eydis Bio’s TAK1 inhibitor acts upstream to interrupt several inflammatory cascades simultaneously, providing a more comprehensive and potentially more effective therapeutic strategy. This novel mechanism holds significant promise for rheumatoid arthritis (RA), a condition where existing standard-of-care treatments often show limited efficacy, tolerability issues, or diminished long-term benefit. In rigorous preclinical models of RA, the TAK1 inhibitor has shown superior efficacy compared to current standard-of-care therapies, significantly reducing inflammation and joint destruction. Importantly, Eydis Bio has generated critical safety data that supports the tolerability and feasibility of targeting TAK1. Eydis Bio’s mission is to bring forward scientifically validated, high-impact therapies that redefine treatment possibilities for patients with autoimmune diseases, beginning with rheumatoid arthritis and expanding to additional high-burden inflammatory indications.

siRNAgen Therapeutics, founded in 2019 as a Bioneer spin-out by Dr. Han Oh Park, is a biotech leader in RNA interference (RNAi) therapies for immunology, fibrosis, and cancer. We aim to address unmet medical needs through our innovative SAMiRNA® platform. Our proprietary SAMiRNA® technology uses self-assembled micelle inhibitory RNA nanoparticles, enabling extrahepatic delivery to organs like the brain, lung, and immune cells. This platform ensures stability, safety, and versatile administration routes, overcoming traditional RNAi limitations. Developed over 20 years, SAMiRNATM supports our growing pipeline. Pipelines Our lead candidate, SRN001, is a novel RNAi therapeutic designed to treat idiopathic pulmonary fibrosis (IPF) by downregulating amphiregulin (AREG), a key driver of fibroblast proliferation and myofibroblast transformation in fibrotic diseases. SRN001 began Phase 1a trials in Australia in 2023 and completed in 2024, marking a significant milestone in our commitment to addressing unmet medical needs in fibrotic diseases globally. Preclinical data show SRN001’s potential in cancer and obesity, expanding its therapeutic scope. Our pipeline also includes innovative programs such as CosmeRNA, a topical RNAi-based cosmetic for androgenetic alopecia, which targets androgen receptor (AR) expression to promote hair regrowth. Launched in Europe in 2023 and in the US in 2025, CosmeRNA has received high safety ratings and certifications. Vision for the future At siRNAgen Therapeutics, our vision is to transform the lives of patients with chronic and complex diseases through sustainable, curative RNAi therapies. By harnessing the SAMiRNA™ platform, we aim to expand the boundaries of RNAi applications beyond traditional liver-targeted therapies, addressing critical challenges in immunology, cancer, and obesity. Our ongoing clinical trials, robust pipeline, and strategic partnerships position us to lead the next wave of RNAi innovation.

Viatris is a global healthcare leader dedicated to empowering individuals to live healthier lives at every stage. Established in 2020 from the combination of two strong legacy companies, we bring together ~32,000 colleagues across nearly 70 countries, delivering innovative healthcare solutions with a deep commitment to sustainability and quality. Headquartered in the U.S., Viatris achieved $14.7 billion in total revenues in 2024 and continues to leverage its capabilities to ensure access to high-quality medicines for nearly 1 billion patients annually. We are at the forefront of addressing critical healthcare needs with products spanning 10+ therapeutic areas and a portfolio including 59 WHO-prequalified products and 250+ medicines on the WHO Essential Medicines List. Our robust global operations include 26 manufacturing and packaging facilities and 10 development centres as of 2025, enabling us to reach over 165 countries and territories. Ranked among the top-20 pharmaceutical companies by revenue, Viatris combines commercial expertise with operational excellence to support partners in bringing therapies to market and creating lasting value.

JW Holdings: Strategic Spin-Out Initiatives for Global Expansion JW Holdings (JWH) comprises 12 affiliated companies focused primarily on healthcare. Among them, JW Pharmaceutical (JWP) is the leading R&D-driven subsidiary. JWP is actively pursuing an open innovation strategy to accelerate the global development of its assets. To enable global clinical advancement, partnering, and exit opportunities, selected programs will be spun out as NewCos or SPCs, incorporated in investor-preferred jurisdictions such as the U.S. or Europe.

Pipeline Assets Presented at BIO Europe

JWP will showcase three innovative assets at BIO Europe. The ophthalmology asset will be featured in the oral presentation, while the other two will be available through 1:1 partnering meetings.

◾ Phase 2–Ready Oral Small Molecule for Ophthalmic Indications (AMD/DME)

◾ Phase 1–Ready First-in-Class Topical Therapeutic for Alopecia.

◾ Orphan Drug Candidate with Potential to Treat Multiple Rare CNS Diseases

Investment & Partnership Opportunities Each program is seeking $15–20 million in strategic or financial investment or licensing partners to initiate clinical studies in the U.S. or Europe.

NewCo/SPC Formation Upon Investment

◾ A NewCo or SPC will be established in the investor’s preferred jurisdiction ◾ The entity will lead clinical development, strategic partnerships, and exit planning

Avelos Therapeutics is a biomarker-driven small molecule oncology drug development company. Avelos particularly focuses on targets in synthetic lethality, DNA damage repair, and cell cycle regulation. The founding members include Young-Whan Park (ex-Merck), Soongyu Choi (ex-Bayer), Kangsik Yun (ex-National Oncoventure), who have strong expertise and networks in novel drug discovery and development. Currently, Avelos has 5 oncology drug programs. AD1208 (MASTLi), a first-in-class DNA damage repair & cell cycle inhibitor program, is currently under Phase 1a in Korea. AD0126 (USP1i), a best-in-class synthetic lethality & DNA damage repair program, is in the preclinical stage. Other programs are in the lead optimization stage. Avelos was founded in Sep. 2021 and is headquartered in Seoul.

Blue Earth Therapeutics is a clinical stage company with a mission to develop radiopharmaceutical therapies that improve patient outcomes by delivering high radiation doses to tumours without compromising on normal organ safety.

CellBion Co., Ltd., established in July 2010, is a pioneer in the radiopharmaceutical industry, specializing in the development and commercialization of innovative radioligand therapies that address unmet medical needs. Our primary focus is on treatment-resistant cancers, such as metastatic castration-resistant prostate cancer (mCRPC), which remain difficult to treat with conventional options like chemotherapy, radiation therapy, and immunotherapies—often limited by modest efficacy and significant side effects due to poor target selectivity. Radioligand therapy (RLT) offers improved safety and efficacy through highly targeted treatment and shows additional promise when combined with immunotherapies by enhancing anti-tumor immune responses. Leveraging cutting-edge RLT technology, CellBion is committed to improving quality of life through innovation. One of our breakthrough products, Lu-177-DGUL (pINN: Pocuvotide satetraxetan), is a radiopharmaceutical agent that selectively targets PSMA-expressing prostate cancer cells using lutetium-177 and a novel DGUL molecule. This approach exploits PSMA overexpression to deliver beta radiation directly to tumors while minimizing damage to healthy tissues. Pocuvotide’s unique molecular design enables rapid clearance from the body, reducing off-target toxicity and side effects. In addition to Pocuvotide, CellBion is actively developing a pipeline of next-generation RLT-based therapeutics and companion diagnostic agents targeting various cancer types.

Digmbio is a small biotech company based in Korea, developing two major assets: a second-generation PARP1-selective inhibitor with high BBB-penetrating properties and a TASR GPCR targeting CNS-related drug. Our lead asset, the second-generation PARP1-selective inhibitor DM5167, has shown potential across four BRCA-mutated cancer types and 15 HRD cancers. Preclinical data indicate that our PARP1 inhibitor outperforms first-generation PARP inhibitors and AstraZeneca's second-generation PARP1 selective inhibitor, Saruparib, in multiple key parameters, particularly in terms of toxicity profile and blood-brain barrier (BBB) penetration potential. Currently, DM5167 is under Phase 1 clinical trials at four major hospitals in Korea. Preliminary data have shown that no hematological toxicity was observed in the 1st and 2nd cohorts at 25 mg and 50mg doses. The human exposure levels were unexpectedly high enough to show a partial response for a patient in the 1st cohort, which is greater than 40 times higher than animal PK with reasonable T1/2. Our neurodegenerative disease asset, DM3159, takes a novel approach by targeting the taste receptor T1R3 to promote neuroprotection and neurogenesis as a disease-modifying therapy, distinguishing it from traditional therapies focused on beta-amyloid or Tau protein. T1R3 is a component of sweet taste receptors and belongs to the G protein-coupled receptor family. Preclinical data for DM3159 demonstrate differentiated efficacy and toxicity, and strong BBB penetration. In a 5xFAD model, the neurogenesis marker DCX was observed in the SGZ and SVZ regions, achieving Pharmacological Proof of Concept. Additionally, in a 3xTG model, DM3159 reduced neuroinflammation in the CA1 and CA3 regions of the hippocampus and showed remarkable behavioral improvement.

FatiAbGen is an antibody engineering biotech company founded in 2020 in Sejong, South Korea. We develop best-in class antibodies adapted to multiple modalities to address diseases with high unmet needs. We collaborate across the Biotech ecosystem to maximize our speed and efficiency for the benefit of patients.

VAR2 Pharmaceuticals (VAR2 Pharma) is a Danish clinical-stage biotech company spun out from the University of Copenhagen in 2012. Our mission is to develop first-in-class therapies for patients with cancer by targeting oncofetal chondroitin sulfate (ofCS) with Vartumabs, our proprietary monoclonal antibodies (mAbs) against ofCS.
VAR2 Pharma's breakthrough moments were the discovery of ofCS and the development of Vartumabs. ofCS is a novel, and now clinically validated, tumor-specific glycosaminoglycan expressed in over 95% of cancer types, largely absent from healthy tissue and driving T-cell exclusion in tumors. Vartumabs are the first mAbs against ofCS. Vartumabs are a significant achievement given that mAbs are often incapable of distinguishing the structurally 'subtle' differences (chain length, sulfation pattern) that distinguish glycosaminoglycans.
Vartumab-based therapies - antibody drug conjugates, CD3-bispecifics and CAR-T's - show high efficacy and safety in mice models with different cancers, including in patient-derived xenografts. Concurrently, Vartumabs show significant diagnostic potential in liquid biopsy detection of ofCS in circulating tumor cells, circulating proteoglycans and extracellular vesicles.
VAR2 Pharma has raised over 30M EUR from private investors and owns all Vartumabs' IP (WO2023148398). Our ongoing first-in-human phase 0 immune-PT/CT imaging trial shows that Vartumabs has highly specific tumor accumulation with minimal off-tumor binding across multiple cancers (lung, rectal and esophageal thus far). Concurrently, we initiated in July 2025 GMP manufacturing of an antibody drug conjugate against ofCS planned to enter clinical trials in Q1 2027.

Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. The company aims to develop scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders. Hoth intends to commercialize drug products under development through partnering with other drug companies. Our current assets are focused in treating a broad range of diseases, including cancer, acne, inflammatory bowel disease, asthma, atopic dermatitis, skin toxicities associated with cancer therapy, TBI/ Stroke and Alzheimer’s disease.

Immuneering is a clinical-stage oncology company outpacing cancer to help patients outlive their disease. The Company’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily deep cyclic inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.

NEX-I discovers proteins associated with immunosuppressive TME, including causal factors.

NEX-I's business model is to research and partner to develop and commercialize the First-in-Class anticancer drugs that target these factors. <NXI-201 partnership available>

• NXI-201 is a preclinical-stage, First-in-Class, fully human mAb(IgG4) neutralizing antibody ; indicated for cancers associated with immunosuppressive TME (CRC, HCC, GC, etc).

• Oncokine-2 is a secretory protein that causes immunosuppressive TME via increase of recruitment and function of MDSC and anti-apoptotic function of tumor itself.

• IND-pkg ready by 1Q 2026.

• Confirmed sufficient anti-cancer effect NXI-201 (mono & combo); confirmed NXI-201 mediated immune cell related gene signature changes & tumor cytotoxicity in ex-vivo human system (CRC patient-derived).

• Validated Oncokine-2 as prognostic/predictive biomarker for optimal patient selection via blood plasma & tissue

<ON-SMRT® partnership available>

• SMRT® is NEX-I's proprietary target discovery platform with an intensive focus on surface antigens associated with immunosuppressive / SoC-refractory tumors.

• The overexpression of specific cell surface proteins in our proprietary animal models suggest SoC-refractory phenotype – and we call it Surface Markers for Refractory Tumor or SMRTs.

• Discovery of SMRTs is applied to the development of targeted therapies such as ADCs (antibody-drug conjugates), BsAbs (bispecific antibodies), and TCEs (T-cell engagers).

OncoVerity is a Colorado based biotechnology company developing precision cancer treatments using a cutting edge computational biology platform. Our focus is on cusatuzumab, a first-in-class high affinity monoclonal antibody targeting CD70, an immune checkpoint target involved in several hematological malignancies, and solid tumors. With a well-tolerated safety profile studied in over 350 patients and promising results in AML, cusatuzumab holds significant therapeutic potential.

We're completing enrollment in a randomized, open-label, multicenter, multinational, Phase 2 trial evaluating the safety and efficacy cusatuzumab combined with venetoclax, and azacitidine to venetoclax and azacitidine in newly diagnosed AML patients not eligible for intensive chemotherapy. The trial is enriched explicitly for patients with limited treatment options who show potential for responding to a cusatuzumab-based regimen, as informed by OncoVerity’s computational approach. We expect interim analyses in Q4 2025, offering a near term value inflection point.

We are actively seeking strategic financing and collaborations to accelerate the expansion of cusatuzumab into additional high-potential indications, maximizing its impact on patient lives and shareholder value.

Innovative biotech focused on innovative small molecule anti-cancer drugs with 8 clinical programs from phase 1 to phase 3, and over 10 preclinical programs, including EGFR TKI, EGFR PROTAC, CDK2/4, CDK4/6, CDK2, CDK7, CDK4, ROS1/NTRK, YAP/TEAD, Exon20ins, RET, PI3K alpha allosteric inhibitor, etc.

Launched IPO in Hong Kong in 2024.

3T Biosciences is an immunotherapy company developing next-generation T cell receptor (TCR)-based therapeutics for cancer and immune-related diseases. Our proprietary 3T-TRACE platform combines high-diversity libraries with active machine learning to discover novel targets and therapeutic TCRs, addressing two major industry challenges: identifying truly tumor-specific targets and predicting TCR specificity and cross-reactivity.

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The Twin platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment.

IO Biotech is advancing its lead cancer vaccine candidate, Cylembio®, in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase 1/2 first line metastatic melanoma data, IO102-IO103, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), has been granted a Breakthrough Therapy Designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York. For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).

CREATE Medicines is an RNA immunotherapy company at the forefront of in vivo CAR development and was the first to bring an in vivo CAR to the clinic in 2023. The company’s approach redefines immunotherapy, opening the door to durable, scalable treatments for previously intractable solid tumors.

Two Phase 1 in vivo CAR trials are ongoing with multiple clinical sites and expansions: MT-302, a TROP2-targeted myeloid CAR in epithelial tumors, and MT-303, a GPC3-targeted myeloid CAR in liver cancer. Notably, MT-303 advanced from concept to clinic in just eight months, underscoring the team’s rapid execution and commitment to getting therapies to patients faster. Data readouts for MT-302 and MT-303 are anticipated at the end of 2025. Additionally, the company’s in vivo CAR NK/myeloid program is quickly approaching the clinic. Myeloid’s stably transduced in vivo CAR T program, which uses retrotransposon technology for nonviral, all-RNA based gene delivery, is also on track.

Myeloid has successfully tackled one of RNA technology’s major hurdles, demonstrating repeat dosing of mRNA products in cancer patients and paving the way for durable and safe anti-tumor responses. The company’s mRNA science and capabilities are unparalleled, achieving over 12 days of sustained expression, longer than any disclosed expression duration from other mRNA or circRNA platforms. Additionally, one patient has safely received more than 20 doses of mRNA-LNP drug product for over a year without any reactogenicity observed.

Myeloid is helping to set the stage for platforms that eliminate the need for complex cell handling and harsh patient lymphodepletion, accelerating adoption and enabling an era in which in vivo CAR treatments become a gold standard of cancer care.

Txinno Bioscience is a dedicated company developing innovative, small molecular and TPD-based anti-cancer treatments to give hope and happiness to patients and their families. Our flagship programs are the ENPP1 inhibitor (TXN10128; Ph1, Innate immunity) and the ULK1 inhibitor/TPD (Lead optimization, RAS/EGFR). Our leadership has successful records of drug development, such as Lazertinib, Zykadia, and K-CAB. Additionally, our senior-level scientists possess expertise in medicinal chemistry (synthesis), biology, ADME, pharmacology, pre-clinical, and clinical research, which enables us to conduct the entire process for early-stage drug development.

Mustbio develops first-in-class and best-in-class, highly tumor-selective immuno-cytokines. Our mission is to precisely harness the power of the immune system, addressing the limitations of conventional cytokine therapies with their narrow safety margins and overcoming the challenges posed by immunotherapies that are ineffective in cold tumors.

Proxygen hunts for glue degraders - small molecules that induce proximity between a target protein and one of hundreds of E3 ligases, leading to the degradation of the target protein via the cell's natural protein recycling machinery.

Boostimmune is a biotech company committed to developing first-in-class therapeutics by targeting innovative and differentiated biological pathways.With a robust pipeline that includes immuno-oncology (IO) therapies, antibody-drug conjugates (ADCs), and immune-stimulating antibody conjugates (ISACs), Boostimmune is positioning itself as a globally competitive biotech driving true innovation in cancer treatment. The core team is composed of experts from global pharmaceutical companies (Genentech, Sanofi) and leading Korean biotechs, including co-founder Dr. Tadatsugu Taniguchi, a world-renowned immunologist from the University of Tokyo, as well as drug development professionals with proven experience in clinical approvals and out-licensing.

Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.
The company uses its proprietary Peptide Drug Conjugate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.

Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.

The company was founded in 2000, has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.
For more information see: www.oncopeptides.com